Venlafaxine (brand name: Effexor or Efexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. First introduced by Wyeth in 1993, now marketed by Pfizer, it is licensed for the treatment of major depressive disorder (MDD), as a treatment for generalized anxiety disorder, and comorbid indications in certain anxiety disorders with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the U.S. retail market, with 17.2 million prescriptions. Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, social phobia, panic disorder, and vasomotor symptoms. At low doses (150mg/day), it acts on serotonergic and noradrenergic systems, whereas at high doses (>300mg/day), it also affects dopaminergic neurotransmission. Multiple double blind studies show venlafaxine's effectiveness in treating depression.
Contributions by Szimonsays, Vanished user kasjqwii3km4tkid, and Mr Bungle.